Alcon Opens New Ophthalmic Pharmaceutical Manufacturing Plant in Singapore to Respond to Growing Eye Care Needs in Asia
Alcon has officially opened the doors to its new state-of-the-art ophthalmic pharmaceutical manufacturing facility in the Tuas Biomedical Park in Singapore. This new facility allows Alcon to be closer and quickly respond to its growing base of customers and patients throughout Asia, who rely on the Alcon portfolio of products for healthy vision.
“The need for quality eye care is increasing rapidly across Asia, as the population grows and ages,” said Roy Acosta, Area President, Alcon Asia-Pacific. “With the opening of this new manufacturing facility, Alcon is making a strong investment in the future of our business in Asia, and ensuring that our innovative products are readily available to those who need them.”
Construction on this 330,000 sq ft facility began in 2009, and represents an investment of approximately S$200 million. The plant produces ophthalmic pharmaceutical products which address eye conditions such as glaucoma, dry eye, allergies and bacterial infections.
“Alcon has more than 20 manufacturing facilities around the world, which use state-of-the-art technology and adhere to the strictest quality standards,” said Acosta. “We are proud to transfer those same capabilities to serve our customers right here in Asia with locally manufactured products.”
Alcon already has experience in operating a manufacturing plant in Singapore. In 2005, the company opened a contact lens manufacturing facility in the Tuas Biomedical Park, to meet the growing demand for DAILIES contact lenses. Singapore has proven to be an attractive manufacturing environment for Alcon.
“Singapore’s robust biomedical presence, and the highly skilled and knowledgeable workforce made it easy to choose Singapore for our new site,” said Christopher Snook, Country President Novartis Singapore and Head Novartis Group Country Management. “With the opening of this facility, we deepen our relationship with Singapore and strengthen the foundation for the long and very successful future Novartis sees in Singapore.”
“Alcon’s first ophthalmic pharmaceutical manufacturing facility in Singapore further strengthens our position as a global biomedical hub. To support this growing sector, Singapore will continue to work with companies to develop dedicated infrastructure, industry-ready talent and new manufacturing capabilities. We look forward to deepening our partnership with Alcon and Novartis to create good jobs and exciting careers in Singapore,” said Mr Yeoh Keat Chuan, Managing Director of the Economic Development Board.
The products manufactured at the new Alcon facility address some of the most widespread eye care needs in the region, such as glaucoma.
To ensure that each product manufactured is of the highest quality, Alcon adheres to the strictest of regulatory and statutory requirements. Through a comprehensive quality management system, Alcon is able to test and monitor all manufacturing processes, and all of its products pass rigorous inspections prior to shipment.
Currently, the facility employs approximately 150 associates, and is expected to continue to grow as production increases.
References
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance